/
Other
Drug
33
Pipeline Programs↗
24
Active Trials↗
54
Companies Involved↗
Drug is a moderately active landscape with 33 programs across 54 companies. The most active players are Bristol-Myers Squibb, Evergreen Therapeutics, Inc., Bayer. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 14
Phase 39
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
31 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.
Analysis
Trial Status
369
clinical trials
Completed301 · 82%
Unknown status20 · 5%
Recruiting15 · 4%
Terminated13 · 4%
Withdrawn8 · 2%
Active, not recruiting5 · 1%
Other7 · 2%
Clinical Trials
Trial Activity
369 trials
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
Recruiting·—·Phase 4·NCT06528431·180 enrolled
Effect of Some Drugs on Rheumatoid Arithritis Activity
Recruiting·—·Phase 3·NCT03770923·75 enrolled
Page 1 of 25
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)